Dato-DXd + Paclitaxel + Nab-paclitaxel + Carboplatin + Capecitabine + Eribulin mesylate
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
May 16, 2022 → Nov 3, 2028
NCT ID
NCT05374512About Dato-DXd + Paclitaxel + Nab-paclitaxel + Carboplatin + Capecitabine + Eribulin mesylate
Dato-DXd + Paclitaxel + Nab-paclitaxel + Carboplatin + Capecitabine + Eribulin mesylate is a phase 3 stage product being developed by Daiichi Sankyo for Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05374512. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05374512 | Phase 3 | Active |
Competing Products
20 competing products in Breast Cancer